Clinical trial aims to address drug deaths linked to street drugs

Drugs <i>(Image: Archive)</i>
Drugs (Image: Archive)
This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The Herald.

A new clinical trial has been launched to address rising drug deaths.

Led by researchers at the University of Stirling, the three-year study will focus on reducing the use of street-sourced benzodiazepines among people receiving treatment for opioid dependency.

Funded by the National Institute for Health and Care Research, the trial will run across seven sites in Scotland and England and beginning in January.

It is among the first studies of its kind and will test whether prescribing a stable dose of diazepam, alongside additional support, can help prevent harmful drug use and reduce drug-related deaths.

Professor Catriona Matheson, who is leading the study, said: "There is a real need for clinically based research within this stigmatised and under-researched population.

"They should have the same access to evidence-based treatment options available across other areas of healthcare in the UK.

"One of the aims of this research is to address that lack of evidence in such a key area of risk relating to drug-related deaths.

"It will inform clinical guidance for drug treatment services that have struggled to support people using multiple substances due to the lack of evidence.

"If successful it will contribute to reducing drug-related deaths, which are a societal challenge."

Benzodiazepines are commonly prescribed to treat anxiety and sleep problems in the short term.

However, their use alongside opioids, such as heroin, is widespread among people who use street drugs.

This combination has been strongly linked to the high rate of drug-related deaths.

While opioid dependency can be treated with methadone or buprenorphine, there is currently no equivalent treatment for people dependent on benzodiazepines.

This gap in care has contributed to the increasing use of unpredictable and often dangerous street-sourced benzodiazepines, which can contain unknown or highly potent substances and are associated with blackouts, overdose, and death.

The trial builds on earlier research and follows a feasibility study funded by the Scottish Government.

Drugs and alcohol policy minister Maree Todd said: "We want to make sure everyone gets the treatment they need.

"I welcome this trial, which follows a successful Scottish Government-funded feasibility study.

"It will help provide an evidence base as we continue to strive to save and improve lives."

The University of Stirling team has developed a new intervention in collaboration with people with lived experience of benzodiazepine use and clinicians.

Participants in the trial will be randomly assigned to receive either the new intervention or standard care, which currently involves a reducing diazepam dose over a maximum of six months according to national guidance.

The new intervention offers a steady prescribed dose of diazepam (up to 30mg), combined with tailored psychological and harm reduction support targeting underlying issues such as anxiety, trauma, and sleep problems.

Researchers will track the use of high-risk street benzodiazepines over a 12-month period using mouth swab laboratory analysis and self-reported data.

They will also monitor overdoses, hospital admissions, mental health, cognitive function, and how acceptable the treatment is to patients.

Professor Matheson said the study will also evaluate cost-effectiveness, saying: "The associated health economic analysis will provide evidence of the most cost-effective treatment option.

"This is essential for ensuring public money is spent appropriately.

"By providing clear clinical and cost effectiveness data our trial will provide commissioners, who are responsible for understanding the local needs for drug treatment and recovery services, and policymakers with direction of what services should be commissioned and how."

The research team will work with a specialist testing centre to monitor emerging synthetic drugs in the street supply, to ensure ongoing safety and relevance of testing protocols.

Participants and clinical staff will be interviewed at three and 12 months to share their experiences and perspectives, helping researchers identify what makes the intervention effective or where barriers may exist.

The trial’s findings are expected to inform future clinical guidance and policy decisions aimed at reducing drug-related deaths and improving treatment for people using multiple substances.

Get involved
with the news

Send your news & photos